Reference
European Medicines Agency. Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri. Internet Document : 12 Feb 2016. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/02/news_detail_002471.jsp&mid=WC0b01ac058004d5c1
Rights and permissions
About this article
Cite this article
Risk of PML with natalizumab: PRAC recommendations. Reactions Weekly 1590, 6 (2016). https://doi.org/10.1007/s40278-016-15058-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-016-15058-5